stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) Return on assets
Travere Therapeutics, Inc.'s return on assets over the twelve months to 30 September 2026 was −17.5%, down 13.3 percentage points from fiscal 2025 (−4.26%). Over the past ten years it has ranged from −46.5% (fiscal 2024) to 36.2% (fiscal 2015); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of −46.1% and above the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −4.26% | 42.24 |
| FY2024 | −46.5% | (31.26) |
| FY2023 | −15.2% | 23.19 |
| FY2022 | −38.4% | (12.41) |
| FY2021 | −26.0% | 1.93 |
| FY2020 | −28.0% | (5.66) |
| FY2019 | −22.3% | (5.59) |
| FY2018 | −16.7% | (5.28) |
| FY2017 | −11.4% | (2.19) |
| FY2016 | −9.23% | (45.43) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | 85.4% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −5.32% |
| TVTX Travere Therapeutics, Inc. | −17.5% |
| CRSP CRISPR Therapeutics AG compare | −19.0% |
| MANE Veradermics Incorporated compare | −20.9% |
| DNTH Dianthus Therapeutics, Inc. compare | −21.8% |
| DFTX Definium Therapeutics, Inc. compare | −51.4% |
| ERAS Erasca, Inc. compare | −65.3% |
| COGT Cogent Biosciences, Inc. compare | −68.0% |
| Biotechnology industry median | −46.1% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on TVTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement